Advertisement
YOU ARE HERE: LAT HomeCollectionsRhone Poulenc Sa
IN THE NEWS

Rhone Poulenc Sa

FEATURED ARTICLES
BUSINESS
March 13, 1990 | LINDA WILLIAMS, TIMES STAFF WRITER
Rhone-Poulenc SA, France's largest pharmaceuticals company, signed an agreement Monday to buy a majority interest in Ft. Washington, Pa.-based Rorer Group and merge its human drug business with Rorer to create one of the world's 10 largest drug companies. Analysts said the two-step transaction--including the issuance of special new rights to all Rorer shareholders--puts a value of $3.2 billion, or $73 a share, on the merger.
ARTICLES BY DATE
BUSINESS
June 27, 1997 | (Associated Press)
The French parent of Rhone-Poulenc Rorer said it is considering a $4.3-billion offer to buy the remaining third of the U.S. drug maker and spin off its own chemicals and fibers business. The move, a sign that parent Rhone-Poulenc wants a larger share of the lucrative Collegeville, Pa., pharmaceutical company's profit, will be considered at the company's board meeting Wednesday. The companies have a "standstill" agreement that bars any acquisition until after the end of next month.
Advertisement
BUSINESS
January 19, 1990 | From Reuters
Rhone-Poulenc S.A., a giant French chemical firm, agreed on Thursday to acquire Rorer Group Inc., in a deal valuing the American drug company at $3.2 billion, the companies said. The newly combined company will be one of the top 10 pharmaceutical companies in the world. It will be led by Robert Cawthorn, who is Rorer's chairman, president and chief executive, the companies said.
BUSINESS
December 20, 1996 | Times Staff and Wire Reports
Merck & Co. and Rhone-Poulenc said they are combining their animal health businesses in a joint venture, creating the world's largest maker of medicines for pets and livestock. The venture, to be called Merial Animal Health, will have yearly sales of about $1.7 billion, leapfrogging Pfizer Inc.'s business to become the world leader in the $10.7-billion market.
BUSINESS
December 20, 1996 | Times Staff and Wire Reports
Merck & Co. and Rhone-Poulenc said they are combining their animal health businesses in a joint venture, creating the world's largest maker of medicines for pets and livestock. The venture, to be called Merial Animal Health, will have yearly sales of about $1.7 billion, leapfrogging Pfizer Inc.'s business to become the world leader in the $10.7-billion market.
BUSINESS
March 14, 1996
ADM, Rhone-Poulenc Form Global Feed Venture: Archer-Daniels-Midland Co. and France's Rhone-Poulenc Animal Nutrition plan to create a global joint venture that will make supplements for animal feed. The venture is expected to generate annual sales of nearly $500 million. Rhone-Poulenc Animal Nutrition is a unit of France's Rhone-Poulenc. The companies said the venture will manufacture premixes, which are blends of amino acids, vitamins, medicinal additives and trace elements, for adding to feed.
BUSINESS
June 27, 1997 | (Associated Press)
The French parent of Rhone-Poulenc Rorer said it is considering a $4.3-billion offer to buy the remaining third of the U.S. drug maker and spin off its own chemicals and fibers business. The move, a sign that parent Rhone-Poulenc wants a larger share of the lucrative Collegeville, Pa., pharmaceutical company's profit, will be considered at the company's board meeting Wednesday. The companies have a "standstill" agreement that bars any acquisition until after the end of next month.
BUSINESS
November 14, 1986
The Danbury, Conn.-based chemical firm said it has reached a definitive agreement to sell the business to the U.S. subsidiary of Rhone-Poulenc S.A., a major French manufacturer of chemicals and pesticides, for $575 million in cash. The sale does not include the agricultural production facilities of Union Carbide India Ltd. Union Carbide said it does not expect to post any material gain or loss on its earnings statement as a result of the sale.
BUSINESS
October 11, 1990 | From Times Wire Services
The French chemical and pharmaceutical giant Rhone-Poulenc SA said today it will slash 3,500 jobs from its Brazilian work force due to government austerity measures that are crimping business activity there. Voluntary layoffs are being conducted at the Sao Paolo-based Rhodia SA, which makes chemicals, fibers and medical products, a company spokeswoman said. "People that leave simply won't be replaced," she said.
BUSINESS
July 11, 1995 | Compiled by Jack Searles
Amgen Inc., the Thousand Oaks biotechnology firm, says encouraging test results have been obtained for a drug it is co-developing with a New York firm to treat amyotrophic lateral sclerosis, or Lou Gehrig's disease. Results have been encouraging enough to begin a third-phase trial, said Amgen and its partner in the project, Regeneron Pharmaceuticals Inc. of Tarrytown, N.Y.
BUSINESS
March 14, 1996
ADM, Rhone-Poulenc Form Global Feed Venture: Archer-Daniels-Midland Co. and France's Rhone-Poulenc Animal Nutrition plan to create a global joint venture that will make supplements for animal feed. The venture is expected to generate annual sales of nearly $500 million. Rhone-Poulenc Animal Nutrition is a unit of France's Rhone-Poulenc. The companies said the venture will manufacture premixes, which are blends of amino acids, vitamins, medicinal additives and trace elements, for adding to feed.
BUSINESS
March 13, 1990 | LINDA WILLIAMS, TIMES STAFF WRITER
Rhone-Poulenc SA, France's largest pharmaceuticals company, signed an agreement Monday to buy a majority interest in Ft. Washington, Pa.-based Rorer Group and merge its human drug business with Rorer to create one of the world's 10 largest drug companies. Analysts said the two-step transaction--including the issuance of special new rights to all Rorer shareholders--puts a value of $3.2 billion, or $73 a share, on the merger.
BUSINESS
January 19, 1990 | From Reuters
Rhone-Poulenc S.A., a giant French chemical firm, agreed on Thursday to acquire Rorer Group Inc., in a deal valuing the American drug company at $3.2 billion, the companies said. The newly combined company will be one of the top 10 pharmaceutical companies in the world. It will be led by Robert Cawthorn, who is Rorer's chairman, president and chief executive, the companies said.
BUSINESS
January 10, 1991 | From Reuters
Eastman Kodak Co. said Wednesday that it will link up its pharmaceutical unit with France's Sanofi SA, in a deal that would create one of the world's top 20 drug companies. Sanofi and Sterling Drug, a unit of Rochester, N.Y.-based Kodak, will set up three joint ventures, opening the huge U.S. market to the French company and strengthening Sterling's presence in Europe. "Our great handicap is we are not present on the American market," Sanofi President Jean-Francois Dehe said.
BUSINESS
March 12, 1990 | From Associated Press
The French chemical giant Rhone-Poulenc SA said today that it has signed a definitive agreement to merge its pharmaceutical business with the U.S. firm Rorer Group Inc. in a deal valued at nearly $1.7 billion. Rorer, based in the Philadelphia suburb of Ft. Washington, is best known for its Maalox antacid. Rhone-Poulenc is in the top 10 in the European pharmaceutical market but has no direct marketing in the United States or Japan.
Los Angeles Times Articles
|